Ex-vivo Expansion of Adult Human Pancreatic Beta-Cells.
Ex-vivo generation of human insulin-producing cells is considered a promising approach to providing an abundant source of cells for beta-cell replacement therapy in diabetes. Expansion of adult beta-cells from the limited number of islet donors is an attractive prospect. However, while evidence supports the replicative capacity of both rodent and human beta-cells in vivo, attempts at expanding these cells in tissue culture result in loss of beta-cell phenotype, making it difficult to track their fate during continuous propagation and raising doubts about their therapeutic potential. Recent lineage-tracing studies demonstrate the ability of human beta-cells to survive and replicate to a significant degree in vitro. Beta-cell delamination out of the normal epithelial structure, a process that results in dedifferentiation, seems to be required for significant in-vitro proliferation. Therefore, ways must be found of inducing redifferentiation of the expanded cells ex vivo, or of restoring their function upon transplantation. Elucidation of the signaling pathways altered during beta-cell adaptation to growth in culture may provide clues to cell redifferentiation. In a recent study, we found that human beta-cell dedifferentiation and entrance into the cell cycle in vitro correlated with activation of the Notch pathway and downregulation of the cell cycle inhibitor p57. Inhibition of the Notch downstream target HES1 using short hairpin RNA reduced beta-cell dedifferentiation and replication, suggesting a potential target for inducing cell redifferentiation following expansion in culture. This review critically discusses the potential for using ex-vivo beta-cell replication and redifferentiation in cell replacement therapy in diabetes.
Efrat
Shimon
S
Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978 Israel.
PLoS Biol. 2007 Jul;5(7):e163
17535113
Biochem Biophys Res Commun. 2006 Mar 10;341(2):291-8
16446152
Diabetes. 2008 Jun;57(6):1575-83
18316362
Mol Cell Endocrinol. 2007 May 30;270(1-2):87-93
17363142
Cell. 2008 Jan 25;132(2):197-207
18243096
Biochem Biophys Res Commun. 2005 Feb 11;327(2):581-8
15629153
Diabetes. 2007 Mar;56(3):703-8
17327439
Nature. 2004 May 6;429(6987):41-6
15129273
J Clin Invest. 2004 Oct;114(7):963-8
15467835
Endocr Rev. 2006 Jun;27(4):356-70
16638909
Biochem Soc Trans. 2008 Jun;36(Pt 3):353-6
18481956
Diabetes. 2001 Feb;50 Suppl 1:S25-9
11272193
Diabetes. 2007 Jan;56(1):3-7
17110468
Cell Prolif. 2008 Jun;41(3):474-91
18422699
Diabetes. 2000 Aug;49(8):1325-33
10923633
Lab Invest. 2006 Feb;86(2):141-53
16402034
Diabetologia. 2008 Jan;51(1):91-100
17994216
Diabetologia. 1979 Feb;16(2):97-100
365659
Diabetes. 2002 Dec;51(12):3435-9
12453897
Diabetes. 2008 Sep;57(9):2413-20
18599525
Diabetes. 2007 Jul;56(7):1802-9
17473224
Diabetes. 2008 Jun;57(6):1584-94
18334605
Diabetes. 2008 Apr;57(4):958-66
18083786
Diabetes. 1995 Dec;44(12):1458-60
7589854
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7999-8004
10884429
J Clin Invest. 2007 Sep;117(9):2553-61
17786244
Diabetologia. 2005 Nov;48(11):2296-304
16193291
J Clin Endocrinol Metab. 1997 Jun;82(6):1852-6
9177395
Stem Cells. 2007 Dec;25(12):3215-22
17901402
J Clin Endocrinol Metab. 2005 Jun;90(6):3401-9
15769977
Cell Death Differ. 2007 Nov;14(11):1860-71
17612586
Diabetes. 2007 May;56(5):1299-304
17303800
Dev Cell. 2007 May;12(5):817-26
17488631
Diabetologia. 2005 Nov;48(11):2221-8
16205882
Stem Cells. 2007 Dec;25(12):3223-33
17901401
Annu Rev Cell Dev Biol. 2006;22:311-38
16824015
Diabetes. 2007 Mar;56(3):699-702
17327438
Science. 2004 Dec 24;306(5705):2261-4
15564314
Diabetes. 1999 May;48(5):1013-9
10331405
Diabetes. 2003 Jan;52(1):102-10
12502499